Rewiring cancer epigenome: lncRNA as modulator of chromatin architecture and neoplastic transformation
Mammalian Genome · 2026
DOI: 10.1007/s00335-025-10172-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mammalian Genome, 2026. Verfasst von Santosh Kumar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Chromatin and Cancer Epigenetics, Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, 110029, India. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Chromatin, Neoplasms, Epigenome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 122 Literaturangaben.
Abstract (Originalsprache)
Epigenetic rewiring modulates gene expression by reshaping chromatin architecture without altering the underlying DNA sequence. The eukaryotic genome is intricately folded within a dynamic three-dimensional nuclear architecture, which is vital for maintaining genomic integrity and ensuring spatially precise gene regulation. Long non-coding RNAs (lncRNAs), a class of regulatory transcripts, play a pivotal role in organizing nuclear structure, preserving cell identity, and sustaining complex regulatory networks. Through interactions with DNA, RNA, transcription factors, and chromatin-modifying complexes, lncRNAs influence the formation and maintenance of higher-order chromatin structures, including topologically associating domains (TADs), lamina-associated domains (LADs), and chromatin loops. These structural frameworks facilitate or constrain long-range genomic interactions, thereby governing transcriptional programs. Aberrant lncRNA expression disrupts this regulatory architecture and is increasingly recognized as a driving force in oncogenesis. Notable lncRNAs, such as XIST, HOTAIR, and MALAT1, modulate gene expression by recruiting epigenetic regulators, including Polycomb Repressive Complex 2 (PRC2), which alters histone modifications and DNA methylation landscapes, and rewires enhancer-promoter contacts. These mechanisms underlie profound transcriptional reprogramming in cancer cells. Technological advances in genome conformation capture methods (e.g., Hi-C, 3C) have enabled high-resolution mapping of these dynamic chromatin interactions, revealing the extent of lncRNA-mediated 3D genome remodeling in malignancy. This review synthesizes emerging evidence on the role of lncRNAs in shaping nuclear architecture and gene regulation, with a focus on their oncogenic and tumor-suppressive functions. By integrating insights into chromatin topology and epigenetic control, we underscore the potential of targeting lncRNAs and associated chromatin remodeling pathways as innovative diagnostic and therapeutic strategies in cancer and other complex diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Chromatin and Cancer Epigenetics, Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, 110029, India.
- Department of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
- Laboratory of Chromatin and Cancer Epigenetics, Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, 110029, India. ashok.sharma@aiims.edu.
- National Cancer Institute, All India Institute of Medical Sciences, Jhajjar, Haryana, India. ashok.sharma@aiims.edu.
ORCID-Profile: Ashok Sharma
Zitieren
APA
Kumar, S., Kundu, S., Sharawat, S. K., & Sharma, A. (2026). Rewiring cancer epigenome: lncRNA as modulator of chromatin architecture and neoplastic transformation. Mammalian Genome. https://doi.org/10.1007/s00335-025-10172-6
Vancouver
Kumar S, Kundu S, Sharawat SK, Sharma A. Rewiring cancer epigenome: lncRNA as modulator of chromatin architecture and neoplastic transformation. Mammalian Genome. 2026. doi:10.1007/s00335-025-10172-6
BibTeX
@article{Kumar2026,
author = {Kumar, Santosh and Kundu, Subhadip and Sharawat, Surender K and Sharma, Ashok},
title = {Rewiring cancer epigenome: lncRNA as modulator of chromatin architecture and neoplastic transformation},
journal = {Mammalian Genome},
year = {2026},
doi = {10.1007/s00335-025-10172-6}
}
EUVIMED